Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRL5Y7
|
|||
| Drug Name |
SPN-812
|
|||
| Synonyms |
Viloxazine hydrochloride; 35604-67-2; 2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride; Emovit; 2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride; ICI 58,834; Viloxazine hydrochloride [USAN]; 2-((2-ethoxyphenoxy)methyl)morpholinehydrochloride; 2-[(2-ethoxyphenoxy)methyl]morpholine;hydrochloride; Morpholine, 2-[(2-ethoxyphenoxy)methyl]-, hydrochloride; Vicilan; Vivalan; 2-[(2-ethoxy phenoxy)methyl]morpholine hydrochloride; Morpholine, 2-((2-ethoxyphenoxy)methyl)-, hydrochloride; Viloxazine hydrochloride (USAN); Viloxazine HCl; CCRIS 1915; Viloxacina clorhidrato; ICI-58834; Viloxacina clorhidrato [Spanish]; EINECS 252-638-6; Prestwick_734; 2-((o-Ethoxyphenoxy)methyl)morpholine hydrochloride; Vivalan (TN); 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride; 2-(2-Ethoxyphenoxymethyl)-2,3,5,6-tetrahydro-1,4-oxazine hydrochloride; rac Viloxazine Hydrochloride; DSSTox_CID_31511; DSSTox_RID_97396; DSSTox_GSID_57722; SCHEMBL300741; CHEMBL2106483; DTXSID8057722; Tox21_113955; 1478AE; AKOS015847050; CCG-220828; NCGC00262964-01; CAS-35604-67-2; A6217; FT-0675815; FT-0675816; FT-0675817; FT-0675818; FT-0675819; D02572; Z-1958; 2-(o-ethoxyphenoxymethyl)morpholine hydrochloride; 604E672; SR-01000872636; SR-01000872636-1; W-110863; 2-(2-Ethoxy-phenoxymethyl)-morpholine; hydrochloride; 2-[(2-Ethoxyphenoxy)-methyl]morpholine hydrochloride; Q27285797; 2-(2-ethoxy-phenoxymethyl)-tetra-hydro-1,4-oxazine hydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 4 | [1] | |
| Company |
Supernus Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C13H20ClNO3
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1OCC2CNCCO2.Cl
|
|||
| InChI |
1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1H
|
|||
| InChIKey |
HJOCKFVCMLCPTP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 35604-67-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2B receptor (HTR2B) | Target Info | Antagonist | [2] |
| Norepinephrine transporter (NET) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| Serotonin receptors | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04786990) Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD (ADHD). U.S. National Institutes of Health. | |||
| REF 2 | New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.